Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin A - Ipsen

Drug Profile

Botulinum toxin A - Ipsen

Alternative Names: AbobotulinumtoxinA; Azzalure; BoNT-A; BTX-A-HAC; BTX-A-HAC NG; Clostridium botulinum toxin type A haemagglutinin complex; Dysport; DYSPORT AESTHETIC; Dysport NG; Dysport RU; Dysport Solution; Dysport® Next Generation; Reloxin

Latest Information Update: 10 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Health Protection Agency Porton Down; Ipsen Limited
  • Developer Biosintetica; Galderma; Ipsen Limited; Medicis Pharmaceutical Corporation; Valeant Pharmaceuticals International
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Skin disorder therapies; Urologics
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Torticollis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Blepharospasm; Equinus foot deformity; Facial wrinkles; Fissure in ano; Glabellar lines; Hyperhidrosis; Muscle spasticity; Neurogenic bladder; Spasm; Torticollis
  • Phase III Musculoskeletal disorders; Overactive bladder; Urinary incontinence
  • Phase II/III Pain
  • Phase II Gilles de la Tourette's syndrome; Hallux valgus; Vulvodynia

Most Recent Events

  • 08 Nov 2019 Ipsen completes a phase II trial in Pain (Treatment-experienced) in United Kingdom (Intradermal) (NCT03663101)
  • 27 Sep 2019 The US FDA approves sBLA application for botulinum toxin A in Muscle spasticity (In adolescents, In children without cerebral palsy) (IM)
  • 12 Sep 2019 Ipsen terminates the phase III CONTENT2 trial in Neurogenic bladder in Belgium, France, Germany, Lithuania, Spain, New Zealand, Chile, Israel, United Kingdom, Argentina, Australia, Brazil, Colombia, Mexico, Peru, Russia, Ukraine due to low recruitment of patients (IM) (NCT02660359)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top